Avantor, Inc., a global provider of essential products and services for the life sciences and advanced technology sectors, has announced the introduction of its pre-engineered PUPSIT assemblies and a full sterile sampling suite. These new offerings are designed to simplify qualification processes, reduce the risk of contamination, and support faster in-process decisions, giving manufacturers more flexibility in configuring, operating, and scaling their bioprocess workflows.

Health Technology Insights: LEO Pharma Showcases New Data at 2025 Dermatology Event

The sterile sampling suite addresses common biomanufacturing challenges with modular, multi-sample configurations that minimize line breaks and reduce operator handling. Standardized bills of materials and accompanying documentation streamline setup and qualification, while closed-path designs protect sample integrity. By offering adaptable components and connection formats tailored to each process, Avantor enables manufacturers to standardize procedures across sites and scales, lowering variability and limiting the need for custom engineering.

Health Technology Insights: MindWalk Names R. Scott Areglado as New CFO

The suite includes multiple solutions to support different sampling needs. The Needle-Based Sampling System, or NBSS, allows closed, aseptic sampling from stainless-steel vessels using a needle interface. The Needle-Free Sampling System, or NFSS, provides a closed, needle-free option that enhances operator safety while maintaining precision and efficiency. Both systems support multi-sample formats and flexible collection options such as bags, bottles, or conical tubes. The Exact Volume Sampling System, or EVSS, delivers highly accurate small-volume sampling, which is especially valuable in cell and gene therapy applications where conserving material is critical. OmniTop provides weld-on or aseptic connections to process vessels, offering flexible chamber options and meeting routine sampling needs with added versatility.

Avantor’s pre-engineered PUPSIT assemblies integrate components compatible with multiple suppliers and connect easily with common filtration setups. By standardizing integrity testing after sterilization and keeping flow paths closed, these assemblies reduce setup variability, simplify implementation, and minimize the need for ad hoc rigging. This helps manufacturers streamline PUPSIT qualification while maintaining full regulatory compliance.

Combined, the sterile sampling suite and PUPSIT assemblies create a consistent, closed pathway from vessel to filter to sample. This approach protects product quality, improves operational safety, lowers risk, and accelerates decision-making across single-use and hybrid facilities, from clinical trials to commercial production. Benoit Gourdier, Executive Vice President of Bioscience Production at Avantor, explained that biopharmaceutical manufacturers require solutions that are configurable, easy to implement, and reliable across scales. He added that these new products, highlighted at CPHI, meet those needs for both established biologics and emerging advanced therapies, helping customers strengthen process control and bring treatments to patients more reliably and quickly.

Health Technology Insights: Hyperfine Enrolls First Patients in PRISM PMR Study

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com